drugset / Trial / NCT03071042
A Clinical Trial of Apatinib Plus Docetaxel in Locally Advanced or Metastatic Gastric or GEJ Adenocarcinoma
NaSingle-groupOpen-labelTreatment
Summary
This study evaluated the tolerance, safety and efficacy of Apatinib plus Docetaxel as the second-line treatment in locally advanced or metastatic gastric cancer (including Gastroesophageal junction (GEJ) Adenocarcinoma).
Timeline
- Start
- 2015-10
- Primary completion
- 2017-12
- Completion
- 2018-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Docetaxel | Small molecule | 60 mg/m2 | Intravenous |
| Subject | Rivoceranib | Small molecule | 425 mg | Oral |
| Subject | Rivoceranib | Small molecule | 500 mg | Oral |
| Subject | Rivoceranib | Small molecule | 675 mg | Oral |
| Subject | Rivoceranib | Small molecule | 750 mg | Oral |